NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Valuation Check As New Psoriasis And Cancer Treatment Milestones Shape Growth Expectations
Johnson & Johnson (JNJ) is back in the spotlight after recent regulatory and clinical milestones, including US approval of ICOTYDE for moderate to severe plaque psoriasis and encouraging early data from an intravesical bladder cancer therapy.
See our latest analysis for Johnson & Johnson.
Despite a steady stream of clinical and regulatory updates, Johnson & Johnson’s share price has had a mixed few months, with a 30 day share price return showing a 2.86% decline, a 90 day share price return...